Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth
Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest report, “Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth” that provides key data, information and analysis of the major trends and issues affecting the biomarkers in cancer research. The report provides a comprehensive insight into the history of biomarkers, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of cancer biomarkers market characterization in terms of its market size, segmentation by key cancer types and the major market drivers and barriers. The report also talks about the patent landscape for cancer biomarkers and provides comprehensive analysis. The report also looks into the cancer biomarkers pipeline along with analysis on the pipeline by indication, phase of development and geography of development. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals. The report also provides detailed analysis of major partnership deals that have taken place in the cancer biomarkers market since 2006 along with segmentation by number of deals per year, indication, deal type, geography and companies. In addition, the report also talks about the major M&A deals in the cancer biomarkers market since 2005 along with segmentation by value, geography and companies. Finally, the report provides the major conclusions from the report.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Scope
The scope of the report includes:
Reasons to buy
The report will enhance your decision making capability. It will allow you to
Summary
GBI Research, the leading business intelligence provider, has released its latest report, “Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth” that provides key data, information and analysis of the major trends and issues affecting the biomarkers in cancer research. The report provides a comprehensive insight into the history of biomarkers, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of cancer biomarkers market characterization in terms of its market size, segmentation by key cancer types and the major market drivers and barriers. The report also talks about the patent landscape for cancer biomarkers and provides comprehensive analysis. The report also looks into the cancer biomarkers pipeline along with analysis on the pipeline by indication, phase of development and geography of development. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals. The report also provides detailed analysis of major partnership deals that have taken place in the cancer biomarkers market since 2006 along with segmentation by number of deals per year, indication, deal type, geography and companies. In addition, the report also talks about the major M&A deals in the cancer biomarkers market since 2005 along with segmentation by value, geography and companies. Finally, the report provides the major conclusions from the report.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Scope
The scope of the report includes:
- Detailed overview of biomarkers in pharmaceutical industry along with their use, efficiency and limitation
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by cancer types including breast cancer, colorectal cancer, prostate cancer, lung cancer, cervical cancer, head and neck cancer, pancreatic cancer, ovarian cancer and stomach cancer
- Key market drivers and restraints shaping the cancer biomarkers market
- Patent analysis of the cancer biomarkers along with segmentation by patent type, company and geography
- Pipeline analysis of the cancer biomarkers along with segmentation by indication, phase and geography
- Analysis of partnership deals from 2006 to 2010 along with segmentation by indication, deal type, geography and companies
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Develop better strategies for cancer biomarkers research by understanding the market dynamics of the cancer biomarker research industry
- Develop market-entry and market expansion strategies by identifying the key cancer areas for high growth and high opportunities
- Understand the factors shaping the cancer biomarkers research market
- Reinforce R&D pipeline by identifying the key biomarker tests which can provide more accurate and early diagnosis of cancer
- Identify the key players best positioned to take the advantage of the opportunities in the global cancer biomarkers research market
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 GBI Research Report Guidance
3 BIOMARKERS OVERVIEW
3.1 History of Cancer Biomarkers
3.2 Use of Cancer Biomarkers
3.2.1 Screening and Early Detection
3.2.2 Diagnosis of Cancer
3.2.3 Prognosis and Measuring Effectiveness of Treatment
3.2.4 Detecting Recurrent Cancer
3.3 Efficiency of Cancer Biomarkers
3.3.1 Speed and Accuracy of Diagnosis
3.3.2 Optimize Costs
3.3.3 Increased Survival Rates
3.3.4 Non Invasive Techniques
3.4 Limitations of Cancer Biomarkers
3.5 Key Takeaway
4 MARKET CHARACTERIZATION
4.1 Market Overview
4.2 Market Size and Forecasts
4.2.1 Segmentation by Indication
4.3 Drivers and Restraints
4.3.1 Market Drivers
4.3.2 Market Barriers
4.4 Key Takeaway
5 PATENT ANALYSIS
5.1 Segmentation by Patent Type
5.2 Segmentation by Company
5.3 Segmentation by Geography
5.4 Key Takeaway
6 PIPELINE ANALYSIS
6.1 Biomarkers in Cancer Research – Pipeline by Indication
6.2 Biomarkers in Cancer Research – Pipeline by Phase
6.3 Biomarkers in Cancer Research – Pipeline by Geography
6.4 Key Takeaway
7 COMPETITIVE LANDSCAPE
7.1 Clarient, Inc.
7.1.1 Business Description
7.1.2 Pipeline
7.1.3 Major Products
7.1.4 Partnership and M&A Deals
7.2 Qiagen N.V.
7.2.1 Business Description
7.2.2 Pipeline
7.2.3 Major Products
7.2.4 Partnership and M&A Deals
7.3 Laboratory Corporation of America Holdings
7.3.1 Business Description
7.3.2 Pipeline
7.3.3 Major Products
7.3.4 Partnership and M&A Deals
7.4 bioMerieux S.A.
7.4.1 Business Description
7.4.2 Pipeline
7.4.3 Major Products
7.4.4 Partnership and M&A Deals
7.5 Biomoda, Inc.
7.5.1 Business Description
7.5.2 Pipeline
7.5.3 Major Products
7.5.4 Partnership and M&A Deals
7.6 Exiqon A/S
7.6.1 Business Description
7.6.2 Pipeline
7.6.3 Major Products
7.6.4 Partnership and M&A Deals
7.7 Beckman Coulter, Inc.
7.7.1 Business Description
7.7.2 Pipeline
7.7.3 Major Products
7.7.4 Partnership and M&A Deals
7.8 A&G Pharmaceutical, Inc.
7.8.1 Business Description
7.8.2 Pipeline
7.8.3 Major Products
7.8.4 Partnership and M&A Deals
7.9 AdnaGen AG
7.9.1 Business Description
7.9.2 Pipeline
7.9.3 Major Products
7.9.4 Partnership and M&A Deals
7.10 Rosetta Genomics, Ltd.
7.10.1 Business Description
7.10.2 Pipeline
7.10.3 Major Products
7.10.4 Partnership and M&A Deals
8 DEALS ANALYSIS
8.1 Partnership Deals
8.1.1 Partnership Deals by Year
8.1.2 Partnership Deals by Indication
8.1.3 Partnership Deals by Deal Type
8.1.4 Partnership Deals by Geography
8.1.5 Partnership Deals by Companies
8.2 M&A Landscape
8.2.1 M&A Deals by Value
8.2.2 M&A Deals by Geography
8.2.3 M&A Deals by Companies
8.2.4 Top Five M&A Deals by Value
8.3 Key Takeaway
9 CONCLUSION
10 APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources
LIST OF TABLES
Table 1: Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016
Table 2: Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 3: Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 4: Biomarkers in Cancer Research, Global, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 5: Biomarkers in Cancer Research, Global, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 6: Biomarkers in Cancer Research, Global, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 7: Biomarkers in Cancer Research, Global, Head & Neck Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 8: Biomarkers in Cancer Research, Global, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 9: Biomarkers in Cancer Research, Global, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 10: Biomarkers in Cancer Research, Global, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016
Table 11: Biomarkers in Cancer Research, Global, Patent Analysis by Company, 2010
Table 12: Biomarkers in Cancer Research, Global, Patent Analysis by Territory, 2010
Table 13: Biomarkers in Cancer Research, Global, Pipeline by Indication and Stage of Development, August 2010
Table 14: Biomarkers in Cancer Research, Clarient Pipeline, August 2010
Table 15: Biomarkers in Cancer Research, Clarient, Major M&A Deals, 2005–2010
Table 16: Biomarkers in Cancer Research, Clarient, Partnership Deals, 2006–2010
Table 17: Biomarkers in Cancer Research, Qiagen Pipeline, August 2010
Table 18: Biomarkers in Cancer Research, Qiagen, Major M&A Deals, 2005–2010
Table 19: Biomarkers in Cancer Research, Qiagen, Partnership Deals, 2006–2010
Table 20: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Pipeline, August 2010
Table 21: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Major M&A Deals, 2005–2010
Table 22: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Partnership Deals, 2006–2010
Table 23: Biomarkers in Cancer Research, bioMerieux Pipeline, August 2010
Table 24: Biomarkers in Cancer Research, bioMerieux, Major M&A Deals, 2005–2010
Table 25: Biomarkers in Cancer Research, bioMerieux, Partnership Deals, 2006–2010
Table 26: Biomarkers in Cancer Research, Biomoda Pipeline, August 2010
Table 27: Biomarkers in Cancer Research, Biomoda, Partnership Deals, 2006–2010
Table 28: Biomarkers in Cancer Research, Exiqon Pipeline, August 2010
Table 29: Biomarkers in Cancer Research, Exiqon, Major M&A Deals, 2005–2010
Table 30: Biomarkers in Cancer Research, Beckman Coulter Pipeline, August 2010
Table 31: Biomarkers in Cancer Research, Beckman Coulter, Major M&A Deals, 2005–2010
Table 32: Biomarkers in Cancer Research, Beckman Coulter, Partnership Deals, 2006–2010
Table 33: Biomarkers in Cancer Research, A&G Pharmaceutical Pipeline, August 2010
Table 34: Biomarkers in Cancer Research, A&G Pharmaceutical, Major M&A Deals, 2005–2010
Table 35: Biomarkers in Cancer Research, AdnaGen Pipeline, August 2010
Table 36: Biomarkers in Cancer Research, AdnaGen, Major M&A Deals, 2005–2010
Table 37: Biomarkers in Cancer Research, AdnaGen, Partnership Deals, 2006–2010
Table 38: Biomarkers in Cancer Research, Rosetta Genomics Pipeline, August 2010
Table 39: Biomarkers in Cancer Research, Rosetta Genomics, Partnership Deals, 2006–2010
Table 40: Biomarkers in Cancer Research, Global, Partnership Deals by Indication, 2006–2010
LIST OF FIGURES
Figure 1: Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016
Figure 2: Biomarkers in Cancer Research, Global, Market Segmentation by Indication, 2009
Figure 3: Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 4: Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 5: Biomarkers in Cancer Research, Global, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 6: Biomarkers in Cancer Research, Global, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 7: Biomarkers in Cancer Research, Global, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 8: Biomarkers in Cancer Research, Global, Head & Neck Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 9: Biomarkers in Cancer Research, Global, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 10: Biomarkers in Cancer Research, Global, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 11: Biomarkers in Cancer Research, Global, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016
Figure 12: Biomarkers in Cancer Research, Market Drivers and Restraints, August 2010
Figure 13: Biomarkers in Cancer Research, Global, Patent Analysis by Patent Type, 2010
Figure 14: Biomarkers in Cancer Research, Global, Patent Analysis by Company, 2010
Figure 15: Biomarkers in Cancer Research, Global, Patent Analysis by Territory, 2010
Figure 16: Biomarkers in Cancer Research, Global, Pipeline by Indication (%), August 2010
Figure 17: Biomarkers in Cancer Research, Global, Pipeline by Phase of Development (%), August 2010
Figure 18: Biomarkers in Cancer Research, Global, Pipeline by Geography (%), August 2010
Figure 19: Biomarkers in Cancer Research, Global, Partnership Deals by Year, 2006–2010
Figure 20: Biomarkers in Cancer Research, Global, Partnership Deals by Indication, 2006–2010
Figure 21: Biomarkers in Cancer Research, Global, Partnership Deals by Deal Type, 2006–2010
Figure 22: Biomarkers in Cancer Research, Global, Partnership Deals by Geography, 2006–2010
Figure 23: Biomarkers in Cancer Research, Global, Partnership Deals by Companies, 2006–2010
Figure 24: Biomarkers in Cancer Research, Global, M&A Deals by Value (%), 2005–2010
Figure 25: Biomarkers in Cancer Research, Global, M&A Deals by Geography (%), 2005–2010
Figure 26: Biomarkers in Cancer Research, Global, M&A Deals by Companies (%), 2005–2010
COMPANIES MENTIONED
Clarient, Inc.
Qiagen N.V.
Laboratory Corporation of America Holdings
bioMerieux S.A.
Biomoda, Inc.
Exiqon A/S
Beckman Coulter, Inc.
A&G Pharmaceutical, Inc.
AdnaGen AG
Rosetta Genomics, Ltd. Skip to top